-
¿¹Ö×Áöanti-tumorÖ÷ҪרעÓÚ³£¼û¶ñÐÔÖ×ÁöÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨1 ÀàеÏÍþ¹ú¼ÊHS-20106×¢ÉäÒº¡¢HS-20105¡¢HS-20117¡¢HS-10516½ºÄÒ¡¢HS-10382Ƭ¡¢HS-10370Ƭ¡¢HS-10386Ƭ¡¢HS-10502Ƭ¡¢HS-10365½ºÄÒ¡¢×¢ÉäÓÃHS-20089/HS-20093¡¢HS-10375Ƭ¡¢HS-10381½ºÄҵȡ£Á˽â¸ü¶à +
¿¹Ö×ÁöÖ÷ҪרעÓÚ³£¼û¶ñÐÔÖ×ÁöÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨1 ÀàеÏÍþ¹ú¼ÊHS-20106×¢ÉäÒº¡¢HS-20105¡¢HS-20117¡¢HS-10516½ºÄÒ¡¢HS-10382Ƭ¡¢HS-10370Ƭ¡¢HS-10386Ƭ¡¢HS-10502Ƭ¡¢HS-10365½ºÄÒ¡¢×¢ÉäÓÃHS-20089/HS-20093¡¢HS-10375Ƭ¡¢HS-10381½ºÄҵȡ£Á˽â¸ü¶à + -
¿¹¸ÐȾanti-infectivesÖ÷ҪרעÓÚ¿¹²¡¶¾¡¢¿¹¸´ÔÓϸ¾ú¸ÐȾ¡¢¿¹Õæ¾ú¸ÐȾÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁÆÖйú³ÉÄêÍâÒõÒõµÀÄîÖé¾ú²¡£¨VVC£©µÄHS-10366ƬµÈ¡£Á˽â¸ü¶à +
¿¹¸ÐȾÖ÷ҪרעÓÚ¿¹²¡¶¾¡¢¿¹¸´ÔÓϸ¾ú¸ÐȾ¡¢¿¹Õæ¾ú¸ÐȾÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁÆÖйú³ÉÄêÍâÒõÒõµÀÄîÖé¾ú²¡£¨VVC£©µÄHS-10366ƬµÈ¡£Á˽â¸ü¶à + -
ÖÐÊàÉñ¾CNS diseasesÖ÷ҪרעÓÚ¾«Éñ¼²²¡¡¢Éñ¾ÏµÍ³¼²²¡µÈÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁƾ«Éñ·ÖÁÑÖ¢µÄ1 ÀàеÏÍþ¹ú¼ÊHS-10380Ƭ¡¢HS-10506ƬµÈ¡£Á˽â¸ü¶à +
ÖÐÊàÉñ¾Ö÷ҪרעÓÚ¾«Éñ¼²²¡¡¢Éñ¾ÏµÍ³¼²²¡µÈÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁƾ«Éñ·ÖÁÑÖ¢µÄ1 ÀàеÏÍþ¹ú¼ÊHS-10380Ƭ¡¢HS-10506ƬµÈ¡£Á˽â¸ü¶à + -
´úл¼°ÆäËümetabolic diseasesÖ÷ҪרעÓÚÌÇÄò²¡¡¢·ÊÅֵȴúлÐÔ¼²²¡ÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨1ÀàеÏÍþ¹ú¼ÊHS-10511Ƭ¡¢HS-20094×¢ÉäÒº¡¢HS-10384 Ƭ¡¢HS-10518½ºÄҵȡ£Á˽â¸ü¶à +
´úл¼°ÆäËüÖ÷ҪרעÓÚÌÇÄò²¡¡¢·ÊÅֵȴúлÐÔ¼²²¡ÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬ÔÚÑÐÏîÄ¿°üÀ¨1ÀàеÏÍþ¹ú¼ÊHS-10511Ƭ¡¢HS-20094×¢ÉäÒº¡¢HS-10384 Ƭ¡¢HS-10518½ºÄҵȡ£Á˽â¸ü¶à + -
×ÔÉíÃâÒßautoimmune diseasesÖ÷ҪרעÓÚ×ÔÉíÃâÒßϵͳ¼²²¡ÁìÓòµÄеÏÍþ¹ú¼ÊÑз¢£¬Èç1ÀàеÏÍþ¹ú¼ÊHS-10374ƬµÈ¡£Á˽â¸ü¶à +
¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚÎÒÃÇ ¤™
-
¿Æ¼¼´´Ð ¤™
-
²úÆ·ÓëÒµÎñ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°Òµ·¢Õ¹ ¤™
